Startups
Draig Therapeutics
Clinical-stage biotechnology company developing investigational medicines for neuropsychiatric disorders through selective modulation of AMPA and GABA receptors. Its lead AMPA receptor potentiator, DT-101, is in Phase 2 studies for major depressive disorder. Co-founded in 2024 by Cardiff University and SV Health Investors, with operations in Cardiff and Massachusetts.
Founded 2024
Team
 Alicja JanuszewiczSVP, People and Culture |
Charlotte AllertonScientific Advisory Board Member |
 Colleen CuffaroBoard Member |
 Douglas WilliamsChairman of the Board |
 Husseini ManjiScientific Advisory Board Member |
 Inder KaulChief Medical Officer |
 Irene MatucciBoard Observer |
 Ivana Magovčević-LiebischPresident and Chief Executive Officer · Board Member |
 Jamil M. BegBoard Member |
 Joanne Palmer-PhillipsSVP, Program Leadership and Portfolio Management |
 Jodie MorrisonBoard Member |
 John AtackHead of Biology and Founder |
John KrystalScientific Advisory Board Member |
 Laetitia SchwabBoard Member |
 Liam RatcliffeBoard Member |
 Maxim SmithDirector, Corporate Development |
 Megan KrenchBoard Observer |
 Natalie SandsSenior Director, Finance |
 Rebecca LuseBoard Observer |
Rob BermanScientific Advisory Board Member |
Roger McIntyreScientific Advisory Board Member |
 Ruth McKernanCo-Founder and Board Member |
 Samantha Budd HaeberleinBoard Member |
 Simon WardChief Scientific Officer and Founder |
 Weeteck YeoSVP, Business Operations and Chief of Staff |